Correlation of ELISA method with three other automated serological tests for the detection of anti-SARS-CoV-2 antibodies

Nguyen N. Nguyen1*, Manohar B. Mutnal1‡, Richard R. Gomez2‡, Huy N. Pham1‡, Lam T. Nguyen1‡, William Koss1, Arundhati Rao1, Alejandro C. Arroliga1, Liping Wang1, Dapeng Wang1, Yinan Hua1, Priscilla R. Powell1†, Li Chen1, Colin C. McCormack1, Walter J. Linz1, Amin A. Mohammad1‡

1 Department of Pathology, Baylor Scott and White Health, Temple, Texas, United States of America, 2 Health Texas Provider Network, Baylor Scott and White Health, Dallas, Texas, United States of America

* These authors contributed equally to this work.
‡ These authors also contributed equally to this work.

Abstract

Public health emergency of SARS-CoV-2 has facilitated diagnostic testing as a related medical countermeasure against COVID-19 outbreak. Numerous serologic antibody tests have become available through an expedited federal emergency use only process. This paper highlights the analytical characteristic of an ELISA based assay by AnshLabs and three random access immunoassay (RAIA) by DiaSorin, Roche, and Abbott that have been approved for emergency use authorization (EUA), at a tertiary academic center in a low disease-prevalence area. The AnshLabs gave higher estimates of sero-prevalence, over the three RAIA methods. For positive results, AnshLabs had 93.3% and 100% agreement with DiaSorin or Abbott and Roche respectively. For negative results, AnshLabs had 74.3% and 78.3% agreement with DiaSorin and Roche or Abbott respectively. All discrepant samples that were positive by AnshLabs and negative by RAIA tested positive by all-in-one step SARS-CoV-2 Total (COV2T) assay performed on the automated Siemens Advia Centaur XPT analyzer. None of these methods, however, are useful in early diagnosis of SARS-CoV-2.

Introduction

The SARS-CoV-2 virus outbreak that began in late 2019 in Wuhan, has a mortality rate of approximately 6.1% worldwide [1–3]. Diagnostic testing is necessary for identifying and isolating infected individuals to limit spread of disease. Molecular testing such as reverse-transcriptase polymerase chain reaction (rtPCR) detects active infection; and serology testing helps identify those who were previously infected (including asymptomatic infections) and have recovered [4, 5]. Nucleic acid detection using rtPCR has become the confirmation test, due to its 99% specificity and 60–90% sensitivity within 7 days of exposure [6] but is faced with numerous supply challenges [7]. The United States Food and Drug Administration (FDA) issued an Emergency Use Approval (EUA) authorization for antibody testing as
complementary to rtPCR, leading to an explosion of new antibody methods, including rapid diagnostic test (RDT), enzyme-linked immunosorbent assay (ELISA), virus neutralization assay (VNA), and chemiluminescent immunoassay (CLIA). These methods offer a range of sensitivities; the RDT provides results in less than 30 min for the presence or absence of antibodies against the virus in a whole blood specimen but has the lowest sensitivity, ELISA and CLIA can quantify antibodies to the virus in about 2–5 hours and 0.5–1 hour respectively in either serum or plasma; while VNA can quantify presence of active antibodies that are able to inhibit virus growth ex vivo, but requires 3–5 days [8, 9]. The best clinical utility of antibody testing for efficient diagnosis at tertiary medical centers remains unclear for screening asymptomatic patients and is being considered for identifying patients with adaptive immune responses for convalescent plasma donor program, or for treating re-positive cases [10]. Additionally the relative performance of many of these assays remains unclear.

We evaluated the performance of COVID-19 serology testing on three random access immunoassay analyzers (RAIA) that are typically found in clinical laboratory across US—Architect i2000 (Abbott Laboratories, Chicago IL), Cobas e601 (Roche Laboratories, Indianapolis, IN), and Liaison XL (DiaSorin, Stillwater, MN)—comparing their performance to an ELISA based assay (AnshLabs, Webster, TX) and rtPCR test (Luminex Corporation, Austin, TX). The ELISA microtiter plate-based immunoassay, was automated on Dynex DSX instrument (Dynex Technologies, Chantilly, VA, USA) for testing IgG and IgM in serum or plasma.

Materials and methods

Specimen selection

This project used randomly selected 167 left-over convenience human serum specimens that were de-identified and stored at –20˚C. The inclusion criteria included i) residual sample volume of > 1.5 mL and ii) documented rtPCR result for SARS-CoV-2. All samples were from patients who were either hospitalized with a confirmed COVID-19 diagnosis, seen in the Emergency Department with symptoms for COVID-19, or were screened for COVID-19 before an elective surgery procedure. Fifteen of the 167 samples were from patients that tested positive by rtPCR with a confirmed COVID-19 clinical diagnosis. These samples were drawn >13 days after rtPCR testing. One hundred and fifty-two serum samples were from patients who tested negative by rtPCR, 134 of these were collected on same day as rtPCR testing. For the remaining 18 samples, the interval between rtPCR and sample collection ranged from 1–48 days. To avoid degradation, the specimens were tested by four methodologies within 12–20 h of each other.

Instrumentation and analysis

Table 1 summarizes the characteristics of the four serologic assays we investigated.

The AnshLabs SARS-CoV2 IgG assay is based on the ELISA technique that measures antibodies to spike and nucleocapsid proteins. It is for in-vitro diagnostic use only and is performed on the Dynex automated analyzer. Serum samples are diluted in a culture tube and transferred to the microtitration wells coated with purified SARS-CoV-2 recombinant antigen. They are incubated for 30 min at 37˚C along with calibrators. The wells are washed and treated with the anti-human IgG antibodies conjugate labeled with peroxidase. After a second incubation and washing step, the wells are incubated with the substrate tetramethylbenzidine (TMB) chromogen solution to induce color change. An acidic stopping solution is added and the degree of enzymatic turnover of the substrate is determined by wavelength absorbance measurement, with 450 nm as the primary filter and 630 nm as the reference filter. The intensity of color change corresponds to arbitrary units of antibody-antigen complex concentration.
present in the specimen. The analyzer calculates antibody concentration in arbitrary concentration units (AU/mL). Samples with AU/mL of $>12$, $10–12$, and $<10$ are considered positive, indeterminate and negative for IgG respectively. It is the only test that uses a three-point calibration curve. The sensitivity and specificity are 95.0% and 98.3% respectively [11].

The Abbott SARS-CoV-2 IgG assay was run on the Abbott Architect i2000SR analyzer that measures IgG antibodies to the nucleocapsid protein. The automated, two-step immunoassay uses chemiluminescent microparticle immunoassay (CMIA) technology for qualitative detection of IgG antibodies in human serum. The sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and diluent are combined and incubated. The antibodies bind to the antigen-coated microparticles. The mixture is washed and anti-human IgG acridinium-labeled conjugate is added. Following incubation, the pre-trigger is added. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). The presence or absence of IgG antibodies is determined by dividing the sample RLU by the stored calibrator RLU to find the IgG assay index (S/C), with a positive cutoff of $\leq 1.4$. The sensitivity and specificity are 100% and 99.63% respectively at $\leq 14$ days post onset of symptoms [12].

The Liaison SARS-CoV-2 S1/S2 IgG is a chemiluminescent immunoassay (CLIA) for detection of anti-S1 and anti-S2 spike glycoprotein specific to SARS-CoV-2 in human serum or plasma on the DiaSorin XL analyzer (Stillwater, MN). Specimen, calibrator, control, coated magnetic particles and diluent are incubated in reaction cuvettes. The antibodies bind to the solid phase through the recombinant S1 and S2 antigens. A second incubation links recombinant S1 and S2 antigens to an isoluminol-antibody conjugate. The starter reagents are then added, and a flash chemiluminescence reaction induced. The light signal, and hence the amount of isoluminol-antibody conjugate, is measured by a photomultiplier and result converted to arbitrary concentration, AU/mL. Samples with AU/mL of $\geq 15$ are considered positive for IgG antibodies. The sensitivity and specificity are 90–97% and 98% respectively $\geq 14$ days post onset of symptoms [13].

The Elecsys Anti-SARS-CoV-2 assay is performed on the Roche cobas e601 analyzer for total antibodies specific for IgG, IgM and IgA which target nucleocapsid protein, in human serum or plasma. A 20uL sample and biotinylated SARS-CoV-2 specific recombinant antigen labeled with ruthenium bind in the first incubation. In the second incubation, streptavidin-coated solid phase microparticles are added to help bind the complex to the solid phase via interaction between biotin and streptavidin. The reaction mixture is aspirated into cells where

Table 1. Characteristics summary of four serologic assays.

|                | Abbott IgG | AnshLabs IgG | Liaison IgG | Elecsys total |
|----------------|------------|--------------|-------------|---------------|
| Analyzer       | Architect i2000SR | Dynex DSX      | DiaSorin Liaison XL | Roche e601    |
| Technique      | Microparticles | ELISA         | Solid phase  | Double sandwich |
| Target         | Nucleocapsid protein | Nucleocapsid & Spike proteins | Spike S1 & S2 proteins | Nucleocapsid protein |
| Antibody       | IgG         | IgG and IgM  | IgG          | IgG, IgM and IgA |
| Conjugate label| Acridinium  | Peroxidase    | Isoluminol   | Ruthenium     |
| Detection      | CMIA        | A450nm        | CLIA         | ECLIA         |
| Calibration    | 2-points    | 3-points      | 2-points     | 2-points      |
| Test run time  | 29 min      | 75 min        | 35 min       | 18 min        |
| Positive cutoff| S/C $\geq 1.4$ | AU/mL of $> 12$ | AU/mL $\geq 15$ | COI $\geq 1.0$ |
| EUA date       | 3/16/2020   | 4/10/2020     | 4/24/2020    | 5/2/2020      |

CMIA = chemiluminescent microparticle immunoassay; A450nm = absorbance at wavelength 450 nm; CLIA = chemiluminescent immunoassay; ECLIA = Electrochemiluminescent immunoassay. S/C = sample control index ratio; AU/mL = arbitrary concentration units; COI = cutoff index.

https://doi.org/10.1371/journal.pone.0240076.t001
microparticles are captured on the surface of electrode, and the unbound substances are washed out with ProCell solution. The ruthenylated-labeled antigen mediates detection via electrochemiluminescence, which is measured by a photomultiplier tube. Results are calculated by software, comparing the electrochemiluminescence signal of the sample to the cutoff value of the calibration as a cutoff index (COI). Samples with COI ≥ 1.0 are considered reactive or positive for anti-SARS-COV-2 antibodies. The sensitivity and specificity are 65.5–100% and 99.81% respectively [14]. The result by all methodologies are reported qualitatively as positive or negative for SARS-COV2.

**Precision and specificity analysis.** The precision studies were carried out by testing pooled positive and negative patient specimens for 5 consecutive days in duplicate. No discrepant results were noted, i.e. all positive and negative were consistent.

**Dilution studies.** In order to rule out non-specific binding, samples that tested positive by ELISA assay were diluted using sample diluent provided in the AnshLabs assay kit. We made and reran samples for a 1:2, 1:3 and 1:4 dilution, and calculated percent recovery.

**Third party adjudication studies.** All ELISA and RAIA discordant samples were evaluated against the FDA emergency used approved all-in-one step SARS-COV-2 Total (COV2T) assay performed on the automated Siemens Advia Centaur XPT analyzer in a reference laboratory.

**Statistical analysis.** All test results were collated using a Microsoft Excel (Microsoft, Redmond, WA) spreadsheet. Statistical comparison was done using qualitative analysis on EP Evaluator Quality Assurance Simplified software (South Burlington, Vermont).

**Results**

The specificities of the validated in-house AnshLabs SARS-CoV-2-IgG and IgM are listed in Table 2. The cross reactivity to anti-influenza B IgG (5 samples), anti-respiratory syncytial virus IgG (5 samples), anti-nuclear antibodies (5 samples), rheumatoid factors (5 samples), anti-influenza A IgG (5 samples), anti-HCV IgG (5 samples), anti-HBV IgG (5 samples), anti-Haemophilus influenza IgG (5 samples) and anti-HIV (5 samples) was determined by testing 45 patient samples obtained before the pandemic and were positive for these analytes. No cross-reactivity was noted for either SARS-CoV-2-IgG or IgM. The clinical sensitivity and specificity using rtPCR results as the gold standard were found to be 86.7% and 91.2% respectively. All samples used for the sensitivity and specificity evaluation were collected from symptomatic patients, either hospitalized inpatients or treated in Emergency Department. The interval between rtPCR confirmation and serology testing ranged from 2–12 days.

Table 3 shows the percent agreement between ELISA and RAIA results for samples that were confirmed positive for SARS-CoV-2 by rtPCR. These samples were collected from symptomatic patients post rtPCR confirmation. ELISA assay correlated best with Total Antibody assay on Roche Elecsys e601 analyzer. This could possibly be attributed to the measurement of IgG antibodies directed towards multiple antigenic proteins (nucleocapsid & spike) by ELISA or measurement of total antibodies (IgG, IgM, and IgA) on Roche Elecsys e601 analyzer.

| Subjects                              | No of samples | IgG (%)       | IgM (%)       |
|---------------------------------------|--------------|---------------|---------------|
| Asymptomatic adults (during COVID-19 outbreak) | 40           | 39/40 = 97.5% | 40/40 = 100%  |
| Presumed negative adults (prepandemic) | 100          | 100/100 = 100%| 100/100 = 100%|
| Presumed negative pediatric (prepandemic) | 39           | 39/39 = 100%  | 39/39 = 100%  |
| Total                                 | 179          | 178/179 = 99.4%| 179/179 = 100%|

https://doi.org/10.1371/journal.pone.0240076.t002
Table 4 shows the agreement between ELISA and RAIA for samples from patients that tested negative for SARS-CoV-2 by rtPCR. The ELISA assay showed an agreement ranging from 74.3–78.3% with different RAIA methodologies: 34, 1, 7, and 5 patients that had tested negative by rtPCR tested positive for antibodies by ELISA, Architect i2000, Liaison XL and Elecsys e601 methodology respectively. All 34 samples that tested positive by ELISA were confirmed positive by Siemens all-in-one step SARS-CoV-2 Total (COV2T) assay on the Siemens Advia Centaur XPT analyzer performed at a nationally acclaimed reference laboratory. This illustrates a higher rate of sero-prevalence is observed by ELISA versus RAIA.

The agreement of ELISA and RAIA results with rtPCR samples tested >13 days previously is shown in Table 5. Nine out of 10 samples tested positive by both rtPCR and all serologic methods. One sample tested negative by rtPCR, but tested positive by all serologic methods. Three RAIA methodologies showed high correlation with nucleic acid test for patient samples that tested negative by rtPCR, with agreements ranging from 95.4–99.3%. The ELISA assay on the other hand showed an agreement of 77.6% for these rtPCR negative samples.

The non-specific binding dilution experiment of the AnshLabs assay showed five samples with various concentration levels of IgG serially diluted to 1:2, 1:4: 1:8 and 1:16. All samples gave a consistent dilution pattern and expected 90–100% recovery of neat sample in AU/mL units (Fig 1).

Discussion

The RAIA methods had 100% and 90% correlation with ELISA and rtPCR respectively for samples collected >13 days post rtPCR confirmation. There were no significant differences among the methods which tested for IgG targeted to one or both nucleocapsid and spike proteins, or tested for total antibodies.

ELISA detected higher sero-prevalence in rtPCR negative samples than the RAIA methods. This may be due to i) higher analytical sensitivity or a lower cutoff by ELISA, which triggered more positive results; ii) cross reactivity to other coronavirus; iii) non-specific binding of other antibodies, for example autoimmune antibodies or deposition of detection antibody on the microtiter well which led to increased absorbance causing false positives. ELISA assays are

Table 3. Agreement of 15 rtPCR positive samples among the serologic methods.

| Agreement between ELISA and RAIA for samples from rtPCR positive patients (n = 15) |                |
|-----------------------------------------------------------------------------------|-----------------|
| AnshLabs IgG vs Architect i2000                                                   | 93.3% (70.2–98.8) |
| AnshLabs IgG vs Liaison XL                                                        | 93.3% (70.2–98.8) |
| AnshLabs IgG vs Elecsys e601                                                      | 100.0% (79.6–100.0) |
| Architect i2000 vs Liaison XL                                                     | 100.0% (79.6–100.0) |
| Architect i2000 vs Elecsys e601                                                   | 93.3% (70.2–98.8) |
| Liaison XL vs Elecsys e601                                                       | 93.3% (70.2–98.8) |

https://doi.org/10.1371/journal.pone.0240076.t003

Table 4. Agreement of 152 rtPCR negative samples among the serologic methods.

| Agreement between ELISA and RAIA for samples from rtPCR negative patients (n = 152) |                |
|-------------------------------------------------------------------------------------|-----------------|
| AnshLabs IgG vs Architect i2000                                                   | 78.3% (71.1–84.1) |
| AnshLabs IgG vs Liaison XL                                                        | 74.3% (66.9–80.6) |
| AnshLabs IgG vs Elecsys e601                                                      | 78.3% (71.1–84.1) |
| Architect i2000 vs Liaison XL                                                     | 96.1% (91.7–98.2) |
| Architect i2000 vs Elecsys e601                                                   | 97.4% (93.4–99.0) |
| Liaison XL vs Elecsys e601                                                       | 94.7% (90.0–97.3) |

https://doi.org/10.1371/journal.pone.0240076.t004
generally known for low detection limits in sub ng/mL to low pg/mL because of their increased incubation time thereby allowing antigen-antibody to reach reaction equilibrium and extra washing steps [15, 16]. The Dynex DSX analyzer used for ELISA assay provided optimization flexibility and automation, which is not available on RAIA due to throughput constraint. Non-specific deposition of other antibodies in patient samples or detection antibody was ruled out by dilution studies for ELISA. Recovery of 90–110% ruled out non-specific binding as a possible cause for false positives (Fig 1). The difference in results for positive and negative samples by RAIA methods may also be due to a higher threshold for positivity.

We believe that higher rate of positivity observed for ELISA i.e. 34 versus 1 by Architect, 7 by Liaison XL and 5 by Elecsys e601, is the net effect of extra washing and longer incubation times used by ELISA or a higher S/C cutoff set in RAIA assays. These are not false positives as claimed in other studies [17, 18] but are true positives not picked up by RAIA. This inadvertently decreases identification of infected patients 5–10 days post infection. The recently released all-in-one step SARS-CoV-2 Total (COV2T) assay performed on the automated

Table 5. Agreement of a) serology systems for rtPCR positives confirmed more than 13 days and b) serology systems for all rtPCR negatives.

| a. Agreement for all rtPCR positive samples drawn > 13 days after rtPCR result (n = 10)          |
|-----------------------------------------------|--------------------------------------------------|
| rtPCR vs ELISA SARS-CoV-2-IgG                | 90.0% (59.6–98.2)                                |
| rtPCR vs Architect i2000 SARS-CoV-2-IgG      | 90.0% (59.6–98.2)                                |
| rtPCR vs Liaison XL SARS-CoV-2 IgG           | 90.0% (59.6–98.2)                                |
| rtPCR vs Elecsys e601 total antibody         | 90.0% (59.6–98.2)                                |

| b. Agreement for all rtPCR negative samples (n = 152)            |
|---------------------------------------------------------------|
| rtPCR vs ELISA SARS-CoV-2-IgG                                 | 77.6% (70.4–83.5)                                |
| rtPCR vs Architect i2000 SARS-CoV-2-IgG                       | 99.3% (96.4–99.9)                                |
| rtPCR vs Liaison XL SARS-CoV-2 IgG                            | 95.4% (90.8–97.8)                                |
| rtPCR vs Elecsys e601 total antibody                          | 96.7% (92.5–98.6)                                |

https://doi.org/10.1371/journal.pone.0240076.e005

Fig 1. Graph of 5 patient samples diluent sets (1/2, 1/4, 1/8, and 1/16) versus AU/mL levels, ruling out non-specific binding in AnshLabs ELISA assay. AU/mL = Arbitrary unit per millilitre, which is provided by the manufacturer.

https://doi.org/10.1371/journal.pone.0240076.g001
Siemens RAIA—Advia Centaur XPT analyzer may have resolved some of these issues and it correlated well with our in-house ELISA assay by detecting all 34 samples that were missed by other RAIA as positives.

**Project limitations**

Our quality assurance project has some notable limitations. At this stage of the disease, true clinical sensitivity and specificity for different methodologies is difficult to determine because of our limited understanding of the disease process and kinetics. Secondly, our assumption that ELISA has better limits of detection is based on circumstantial evidence, as certified standards quantifying limits of detection on different platforms are not available. Third, the cutoffs provided by manufacturers were relied on which may not have undergone extensive validation. Establishing laboratory specific cut-off is akin to establishing reference ranges, which is highly dependent on prevalence of disease in local population.

**Conclusion**

All of the assays we investigated would work well for epidemiological sero-prevalence studies. Among rtPCR negative patients, ELISA gave higher estimates of sero-prevalence in our dataset and would probably do so in population-based epidemiological surveys using serological testing. RAIA methods could however offer other advantages over ELISA which includes i) faster turnaround time; ii) random access to allow immediate testing; iii) longer calibration stability, obviating the need to perform daily calibration as required by ELISA; iv) the ability to perform other immunoassay testing concurrently; and v) higher test throughput and walk away capabilities. However in conclusion, no serological method tested has sensitivity and specificity greater than or equal to 99% for one to 5 days post exposure, limiting their use in early diagnosis.

**Supporting information**

S1 Raw data.
(XLSX)

**Acknowledgments**

The authors would like to thank Ms. Briget Da Graca for editorial revision. We also acknowledge Ms. Laura Gonzales and her team from Health Texas Provider Network (Dallas, TX) for blinded testing of discrepant samples between ELISA and RAIA methods using Siemens Centaur total antibody assay.

**Author Contributions**

**Conceptualization:** Nguyen N. Nguyen, Manohar B. Mutnal, Arundhati Rao, Amin A. Mohammad.

**Data curation:** Nguyen N. Nguyen, Amin A. Mohammad.

**Formal analysis:** Nguyen N. Nguyen, Amin A. Mohammad.

**Funding acquisition:** Nguyen N. Nguyen, Arundhati Rao, Amin A. Mohammad.

**Investigation:** Nguyen N. Nguyen, Manohar B. Mutnal, Liping Wang, Dapeng Wang, Yinan Hua, Priscilla R. Powell, Li Chen, Colin C. McCormack, Walter J. Linz, Amin A. Mohammad.
Methodology: Nguyen N. Nguyen, Manohar B. Mutnal, Richard R. Gomez, Huy N. Pham, Lam T. Nguyen, Amin A. Mohammad.

Project administration: Nguyen N. Nguyen, William Koss, Amin A. Mohammad.

Resources: Nguyen N. Nguyen, Arundhati Rao, Alejandro C. Arroliga, Amin A. Mohammad.

Software: Nguyen N. Nguyen, Amin A. Mohammad.

Supervision: Nguyen N. Nguyen, William Koss, Amin A. Mohammad.

Validation: Nguyen N. Nguyen, Manohar B. Mutnal, Richard R. Gomez, Huy N. Pham, Lam T. Nguyen, Amin A. Mohammad.

Visualization: Nguyen N. Nguyen, Amin A. Mohammad.

Writing – original draft: Nguyen N. Nguyen, Amin A. Mohammad.

Writing – review & editing: Nguyen N. Nguyen, Manohar B. Mutnal, Richard R. Gomez, Huy N. Pham, William Koss, Arundhati Rao, Alejandro C. Arroliga, Amin A. Mohammad.

References

1. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. The New England journal of medicine. 2020; 382(10):929–36. Epub 2020/02/01. https://doi.org/10.1056/NEJMoa2001191 PMID: 32004427

2. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [cited 18 June 2020]. Available from: https://covid19.who.int/.

3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine. 2020; 382(8):727–33. Epub 2020/01/25. https://doi.org/10.1056/NEJMoa2001017 PMID: 31978945

4. Okba NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. 2020:2020.03.18.20038059. https://doi.org/10.1101/2020.03.18.20038059

5. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020. Epub 2020/03/30. https://doi.org/10.1093/cid/ciaa344 PMID: 32221519

6. Shen M, Zhou Y, Ye J, Abdullah Al-Maskri AA, Kang Y, Zeng S, et al. Recent advances and perspectives of nucleic acid detection for coronavirus. Journal of pharmaceutical analysis. 2020. Epub 2020/04/16. https://doi.org/10.1016/j.jpha.2020.02.010 PMID: 32292623

7. European Centre for Disease Prevention and Control. Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK–sixth update–12 March 2020. Stockholm: ECDC, 2020.

8. Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A, Krogfelt KA, et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv. 2020:2020.04.09.20056325. https://doi.org/10.1101/2020.04.09.20056325

9. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020:2020.03.30.20047365. https://doi.org/10.1101/2020.03.30.20047365

10. Korean Center for Disease Control and Prevention. Findings from investigation and analysis of re-positive cases 2020 [cited June 18 2020]. Available from: https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030&act=view&list_no=367267&nPage=1.

11. AnshLabs. SARS-CoV2 IgG ELISA IL-1001 IVD Use for Dynex Analyzer 2020 [cited 18 June 2020]. Available from: https://www.anshlabs.com/product/sars-cov2-igg-elsa/.

12. Abbott. SARS-COV-2 IMMUNOA Ssays 2020 [cited 18 June 2020]. Available from: https://www.corelaboratory.abbott/us/en/offe rings/segments/infectious-disease/sars-cov-2.

13. DiaSorin. LIAISON® SARS-CoV-2 S1/S2 IgG 2020 [cited 18 June 2020]. Available from: https://www.diasorin.com/sites/default/files/allegati/liaisonr_sars-cov-2_s1s2_igg_brochure.pdf.pdf.
14. Roche Diagnostics. Elecsys® Anti-SARS-CoV-2 2020 [cited 18 June 2020]. Available from: https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html.

15. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Current protocols in microbiology. 2020; 57(1):e100. Epub 2020/04/18. https://doi.org/10.1002/cpmc.100 PMID: 32302069

16. Zhang S, Garcia-D’Angeli A, Brennan JP, Huo Q. Predicting detection limits of enzyme-linked immunosorbent assay (ELISA) and bioanalytical techniques in general. The Analyst. 2014; 139(2):439–45. Epub 2013/12/07. https://doi.org/10.1039/c3an01835k PMID: 24308031

17. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. Clinical Performance of Two SARS-CoV-2 Serologic Assays. Clinical Chemistry. 2020. https://doi.org/10.1093/clinchem/hvaa120 PMID: 32402061

18. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. Clinical Chemistry. 2020. https://doi.org/10.1093/clinchem/hvaa132 PMID: 32484860